NO20011664L - Sammensetning med höy renhet omfattende (7<alfa>, 17<alfa>)- 17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on - Google Patents

Sammensetning med höy renhet omfattende (7<alfa>, 17<alfa>)- 17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on

Info

Publication number
NO20011664L
NO20011664L NO20011664A NO20011664A NO20011664L NO 20011664 L NO20011664 L NO 20011664L NO 20011664 A NO20011664 A NO 20011664A NO 20011664 A NO20011664 A NO 20011664A NO 20011664 L NO20011664 L NO 20011664L
Authority
NO
Norway
Prior art keywords
alpha
pregn
hydroxy
methyl
high purity
Prior art date
Application number
NO20011664A
Other languages
English (en)
Other versions
NO20011664D0 (no
NO317427B1 (no
Inventor
Peter Huub Gerard Kirchholtes
Gerard Arnoud Jozef Maria Sas
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234220&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20011664(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of NO20011664D0 publication Critical patent/NO20011664D0/no
Publication of NO20011664L publication Critical patent/NO20011664L/no
Publication of NO317427B1 publication Critical patent/NO317427B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0081—Substituted in position 17 alfa and 17 beta
    • C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0096—Alkynyl derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
NO20011664A 1998-10-16 2001-04-03 Sammensetning med hoy renhet omfattende (7<alfa>, 17<alfa>)-17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on NO317427B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203460 1998-10-16
PCT/EP1999/007768 WO2000023460A1 (en) 1998-10-16 1999-10-11 HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE

Publications (3)

Publication Number Publication Date
NO20011664D0 NO20011664D0 (no) 2001-04-03
NO20011664L true NO20011664L (no) 2001-04-03
NO317427B1 NO317427B1 (no) 2004-10-25

Family

ID=8234220

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011664A NO317427B1 (no) 1998-10-16 2001-04-03 Sammensetning med hoy renhet omfattende (7<alfa>, 17<alfa>)-17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on

Country Status (30)

Country Link
US (3) US6969708B1 (no)
EP (2) EP1275379A3 (no)
JP (1) JP2002527525A (no)
KR (3) KR20050003358A (no)
CN (2) CN100378116C (no)
AR (1) AR020832A1 (no)
AT (1) ATE239032T1 (no)
AU (1) AU763232B2 (no)
BR (1) BR9914441A (no)
CA (1) CA2344686C (no)
CO (1) CO5160271A1 (no)
CZ (1) CZ298703B6 (no)
DE (1) DE69907495T2 (no)
DK (1) DK1121375T3 (no)
ES (1) ES2197677T3 (no)
HK (1) HK1039620B (no)
HU (1) HUP0104206A3 (no)
ID (1) ID28463A (no)
IL (1) IL141850A (no)
NO (1) NO317427B1 (no)
NZ (1) NZ510501A (no)
PE (1) PE20001377A1 (no)
PL (1) PL197870B1 (no)
PT (1) PT1121375E (no)
RU (1) RU2220975C2 (no)
SK (1) SK284569B6 (no)
TR (2) TR200504091T2 (no)
TW (2) TW577893B (no)
WO (1) WO2000023460A1 (no)
ZA (1) ZA200101952B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL356465A1 (en) * 2002-10-04 2004-04-05 ANPHARM Przedsiębiorstwo Farmaceutyczne S.A. METHOD OF MANUFACTURE OF 17beta-HYDROXY-7alpha-METHYL-19-NOR-17alpha-PREGN-5(10)-ENE-20-YNE-3-ONE
TW200418525A (en) * 2002-11-20 2004-10-01 Akzo Nobel Nv Coated pharmaceutical tablets containing Tibolone
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
WO2005117899A1 (en) * 2004-06-02 2005-12-15 Cipla Limited Pharmaceutical composition comprising tibolone and process for procuding the same
CA2594717C (en) 2005-02-01 2015-01-20 F. Hoffmann-La Roche Ag Ibandronate polymorph b
BRPI0607092A2 (pt) 2005-02-01 2009-08-04 Hoffmann La Roche polimorfo cristalino de monoidrato de sal monossódico de ácido 3-(n-metil-n-pentil) amino-1-hidroxipropano-1, 1-difosfÈnico, ibandronato, processo para a preparação de um polimorfo de ibandronato cristalino, e composição farmacêutica que o compreende
EP1883648A1 (en) * 2005-05-23 2008-02-06 Newchem S.p.A. Process for the preparation of pure crystalline tibolone
CZ300465B6 (cs) * 2007-07-25 2009-05-27 Zentiva, A. S. Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
ITMI20130120A1 (it) * 2013-01-25 2014-07-26 Ind Chimica Srl Processo per la preparazione in forma cristallina di tibolone, (7alfa,17alfa)-17-idrossi-7-metil-19-norpregn-5(10)-en-20-in-3-one
CA3122854A1 (en) * 2018-12-17 2020-06-25 Aimmune Therapeutics, Inc. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CN114409717B (zh) * 2021-12-17 2023-03-17 湖南科益新生物医药有限公司 替勃龙中间体醚化物和替勃龙的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE665514A (no) 1964-06-16
CH488682A (de) 1965-07-30 1970-04-15 Ciba Geigy Verfahren zur Herstellung von 4,9,11-Trienen der 19-Nor-androstanreihe
NL146838B (nl) 1966-06-24 1975-08-15 Organon Nv Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
US3515719A (en) 1967-03-15 1970-06-02 Upjohn Co 7-methyl-6,19-epoxy steroids of the androstane series
US4701450A (en) 1984-03-21 1987-10-20 Akzo N.V. Steroids for use as immunomodulators
JPH03503414A (ja) 1988-03-25 1991-08-01 アクゾ・エヌ・ヴエー フッ化物塩を含有する医薬製剤
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
ZA941464B (en) * 1993-03-05 1994-09-27 Akzo Nv Use of pregnane derivative
IL115445A (en) * 1994-10-17 1999-08-17 Akzo Nobel Nv Solid pharmaceutical compositions comprising low dosage active ingredient oil and excipient capable of binding water and their preparation
IL123422A (en) * 1997-03-05 2003-05-29 Akzo Nobel Nv USE OF 7alpha-METHYL-17alpha-ETHYNYL-ESTRANE DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR THE TREATMENT OF ATHEROSCLEROSIS
IL123984A (en) * 1997-04-22 2004-09-27 Akzo Nobel Nv Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable

Also Published As

Publication number Publication date
SK284569B6 (sk) 2005-06-02
US20050245496A1 (en) 2005-11-03
NZ510501A (en) 2003-10-31
EP1275379A2 (en) 2003-01-15
ID28463A (id) 2001-05-24
ES2197677T3 (es) 2004-01-01
TR200101083T2 (tr) 2001-08-21
IL141850A0 (en) 2002-03-10
SK4932001A3 (en) 2001-12-03
PL347264A1 (en) 2002-03-25
IL141850A (en) 2005-11-20
AU6202999A (en) 2000-05-08
KR20060071897A (ko) 2006-06-27
CN100432093C (zh) 2008-11-12
CZ298703B6 (cs) 2007-12-27
US6969708B1 (en) 2005-11-29
BR9914441A (pt) 2001-06-26
CN1322210A (zh) 2001-11-14
KR20050003358A (ko) 2005-01-10
TR200504091T2 (tr) 2006-05-22
HK1039620A1 (en) 2002-05-03
CA2344686A1 (en) 2000-04-27
ATE239032T1 (de) 2003-05-15
DK1121375T3 (da) 2003-08-04
KR100635018B1 (ko) 2006-10-17
EP1275379A3 (en) 2003-03-26
CO5160271A1 (es) 2002-05-30
JP2002527525A (ja) 2002-08-27
HUP0104206A2 (hu) 2002-04-29
PT1121375E (pt) 2003-07-31
PL197870B1 (pl) 2008-05-30
CN100378116C (zh) 2008-04-02
CZ2001976A3 (cs) 2001-08-15
HK1039620B (zh) 2003-08-22
PE20001377A1 (es) 2000-12-09
TW200403251A (en) 2004-03-01
RU2220975C2 (ru) 2004-01-10
NO20011664D0 (no) 2001-04-03
WO2000023460A1 (en) 2000-04-27
TW577893B (en) 2004-03-01
AU763232B2 (en) 2003-07-17
KR20010080133A (ko) 2001-08-22
EP1121375A1 (en) 2001-08-08
EP1121375B1 (en) 2003-05-02
ZA200101952B (en) 2002-06-10
NO317427B1 (no) 2004-10-25
DE69907495D1 (de) 2003-06-05
US20040248870A1 (en) 2004-12-09
CN1769293A (zh) 2006-05-10
HUP0104206A3 (en) 2002-06-28
AR020832A1 (es) 2002-05-29
CA2344686C (en) 2009-04-28
DE69907495T2 (de) 2004-05-06

Similar Documents

Publication Publication Date Title
ID26186A (id) Komposisi sampo
ID28694A (id) Komposisi sampo
MA27349A1 (fr) Composition cristalline renfermant de l&#39;escitalopram.
ID29430A (id) Komposisi herbisida
DK0945132T3 (da) Ibuprofen-præparat
ID26720A (id) Komposisi oral
EP1016400A4 (en) COMPOSITION FOR EXTERNAL USE
EE200000693A (et) Uudsed makroosakeste formulatsioonid
PT941998E (pt) Antibioticos macrolidos do tipo 3,6-cetal
ATE241597T1 (de) Geruchsmaskierte dimethylsulfid-zusammensetzung
DE69942892D1 (de) Gaserzeugende zusammensetzung
DE69928862D1 (de) Zusammensetzung
NO20011190L (no) Keramiske karbonsammensetninger
NO992470L (no) 2-amidazolinyl-amino-indolforbindelser anvendelige som &lt;alfa&gt;-2-adreno-reseptoragonister
NO20013013D0 (no) &lt;alfa&gt;v&lt;beta&gt;6-integrininhibitorer
NO20011664D0 (no) Sammensetning med höy renhet omfattende (7&lt;alfa&gt;, 17&lt;alfa&gt;)- 17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on
NO971248D0 (no) 5&lt;alfa&gt;-reduktaseinhibitorer
EP1031880A4 (en) POSITIVE RADIATION-SENSITIVE COMPOSITION
ID26295A (id) Komposisi keras-ultraviolet
GC0000101A (en) Novel composition for the prophylaxis of hepatitis.
ID26485A (id) Komposisi paroksetina
DE998539T1 (de) Kühlmittelzusammensetzung
ID28359A (id) Komposisi
DE69939964D1 (de) Gelförmige Zusammensetzung
DE59909590D1 (de) Azidfreie, gaserzeugende zusammensetzung

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees